| Literature DB >> 23911197 |
Guillaume Gros1, Lorena Martinez, Anna Servat Gimenez, Paula Adler, Philippe Maurin, Roland Wolkowicz, Pierre Falson, Jens Hasserodt.
Abstract
Non-peptidomimetic drug-like protease inhibitors have potential for circumventing drug resistance. We developed a much-improved synthetic route to our previously reported inhibitor candidate displaying an unusual quaternized hemi-aminal. This functional group forms from a linear precursor upon passage into physiological media. Seven variants were prepared and tested in cellulo with our HIV-1 fusion-protein technology that result in an eGFP-based fluorescent readout. Three candidates showed inhibition potency above 20μM and toxicity at higher concentrations, making them attractive targets for further refinement. Importantly, our class of original inhibitor candidates is not recognized by two major multidrug resistance pumps, quite in contrast to most clinically applied HIV-1 protease inhibitors.Entities:
Keywords: Antiviral agents; Cellular assay; Chemical synthesis; Cyclic urea; HIV-1 protease inhibitors; Quaternary hemiaminal; Transition-state isostere
Mesh:
Substances:
Year: 2013 PMID: 23911197 DOI: 10.1016/j.bmc.2013.06.018
Source DB: PubMed Journal: Bioorg Med Chem ISSN: 0968-0896 Impact factor: 3.641